Related Experiment Videos
Tumor-targeted cell killing with 8-hydroxyquinolyl-glucuronide
K J Henle1, T P Monson, W A Nagle
1Department of Medicine, University of Arkansas for Medical Sciences, Little Rock.
Abstract:
Many tumors show elevated levels of hydrolytic enzymes that may be associated with invasive processes. The RIF-1 murine tumor has levels of beta-glucuronidase that are more than four times higher than those in liver. Elevated tumor glucuronidase levels can be used as a basis for tumor-targeted therapy when systemically administered glucuronides of cytotoxic drugs are deconjugated preferentially at the tumor site. In this study we have used 8-hydroxyquinoline (8-OHQ) as a model compound for such a tumor-targeting concept. We showed that RIF tumors and spleen had the highest beta-glucuronidase activity in C3H mice; for example, RIF tumors released approximately seven times more phenolphthalein per gram of tissue from its glucuronide than liver, when compared under identical conditions. In vitro, low concentrations of 8-OHQ that might be achievable in vivo, ranging from 1 to 10 microM reduced cell survival by four orders of magnitude, while 1 mM 8-hydroxyquinolyl-glucuronide (1 h, 37 degrees C) resulted in only modest (S = 54%) cytotoxicity. Combination treatments of 8-OHQ (2.5 or 5 microM) with either hyperthermia or X radiation did not significantly change the slope of survival curves for RIF tumors in vitro, but suggest that targeted 8-OHQ toxicity combined with local hyperthermia and/or irradiation may be useful for significantly increasing therapeutic gains in vivo.
Insights
Elevated beta-glucuronidase in RIF-1 tumors suggests a novel cancer therapy. Targeting this enzyme with 8-hydroxyquinoline (8-OHQ) glucuronides may enhance drug delivery and efficacy for improved tumor treatment.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Tumors often exhibit elevated hydrolytic enzyme levels, potentially linked to invasive processes.
- The RIF-1 murine tumor model displays significantly higher beta-glucuronidase activity compared to liver tissue.
- Elevated tumor beta-glucuronidase presents a therapeutic target for enzyme-activated prodrug strategies.
Purpose of the Study:
- To investigate the potential of targeting elevated beta-glucuronidase in RIF-1 tumors using 8-hydroxyquinoline (8-OHQ) as a model compound.
- To evaluate the efficacy of systemically administered 8-hydroxyquinolyl-glucuronide for tumor-specific drug release and cytotoxicity.
- To explore combination therapies involving 8-OHQ, hyperthermia, and X-radiation for enhanced anti-tumor effects.
Main Methods:
- Assessed beta-glucuronidase activity in RIF-1 tumors and liver tissue of C3H mice.
- Quantified phenolphthalein release from its glucuronide in RIF tumors versus liver.
- Performed in vitro cytotoxicity assays using 8-OHQ and 8-hydroxyquinolyl-glucuronide on RIF tumor cells.
- Investigated the effects of combining 8-OHQ with hyperthermia or X-radiation on RIF tumor cell survival.
Main Results:
- RIF-1 tumors exhibited substantially higher beta-glucuronidase activity than liver tissue, releasing significantly more phenolphthalein from its glucuronide.
- Low concentrations of 8-OHQ (1-10 microM) demonstrated potent in vitro cytotoxicity against RIF tumor cells.
- 8-hydroxyquinolyl-glucuronide showed only modest cytotoxicity, indicating limited prodrug activation at the tested concentration.
- Combination treatments of 8-OHQ with hyperthermia or X-radiation did not significantly alter RIF tumor cell survival curves in vitro.
Conclusions:
- Elevated beta-glucuronidase in RIF-1 tumors provides a basis for targeted prodrug therapy.
- While 8-hydroxyquinolyl-glucuronide showed limited direct cytotoxicity, the concept of targeted 8-OHQ delivery is promising.
- Further in vivo studies are warranted to explore the therapeutic potential of combining targeted 8-OHQ delivery with local hyperthermia and/or irradiation for enhanced cancer treatment.